Revvity Acquires ACD/Labs to Revolutionize Scientific Workflow Software
Revvity, Inc. has announced the acquisition of ACD/Labs, a global provider of software solutions for analytical characterization and molecular design in the pharmaceutical and materials science sectors. The transaction is expected to close by the end of Q4 2025.
The acquisition will bring extensive benefits to both companies and their customers. Kevin Willoe, President of Revvity Signals Software, sees this as an opportunity to create a unified SaaS environment for pharmaceutical and materials science customers. This will bridge the gap between analytical data and actionable insights, allowing for more informed decision-making.
ACD/Labs, with its expertise in supporting analytical and process workflows, will strengthen Revvity's ability to accelerate scientific innovation. The acquisition also expands the scope and depth of Revvity Signals’ offerings, providing comprehensive support across the entire scientific workflow. Daria Thorp, President and CEO of ACD/Labs, is excited about the acquisition, stating that it will expand the reach of their technology and deliver unified end-to-end solutions.
The acquisition of ACD/Labs by Revvity, Inc. is set to close by the end of 2025. This strategic move aims to unify software solutions for pharmaceutical and materials science sectors, enhancing the entire scientific workflow and accelerating innovation.
